Mithra and Rafa Laboratories sign binding Head of Terms to commercialize DONESTA® in Israel
December 21, 2023 11:45 ET
|
Mithra Pharmaceuticals
Mithra and Rafa Laboratories sign binding Head of Terms to commercialize DONESTA® in Israel Rafa Laboratories to receive the exclusive commercial rights for DONESTA® in Israel on the...
Mithra Completes Pediatric Study of ESTELLE® in Adolescent Patients
December 20, 2023 11:45 ET
|
Mithra Pharmaceuticals
Mithra Completes Pediatric Study of ESTELLE® in Adolescent Patients Important milestone for Mithra’s commitment to bring benefits of ESTELLE® to more womenPotential EMA approval in pediatric...
Mithra Receives Positive DSMB Opinion on DONESTA® European Phase 3 Trial
December 18, 2023 01:00 ET
|
Mithra Pharmaceuticals
Mithra Receives Positive DSMB Opinion on DONESTA® European Phase 3 Trial The DSMB recommends continuing the phase 3 trial in Europe following regular safety assessmentThe menopause phase 3 program...
Mithra and Gedeon Richter sign binding Head of Terms to commercialize ESTELLE® and DONESTA® in China
December 04, 2023 01:00 ET
|
Mithra Pharmaceuticals
Mithra and Gedeon Richter sign binding Head of Terms to commercialize ESTELLE® and DONESTA® in China Mithra signs binding Head of Terms for a twenty-year partnership with Gedeon-Richter...
Mithra receives guidance from the FDA for the DONESTA® NDA marketing authorization filing in the United States
November 30, 2023 01:00 ET
|
Mithra Pharmaceuticals
Mithra receives guidance from the FDA for the DONESTA® NDA marketing authorization filing in the United States DONESTA® for the treatment of vasomotor symptoms of menopause, is expected to target...
Mithra to hold five presentations on key role of estrogens in women’s health, including Estetrol (E4), at the ESG Congress in Amsterdam
November 28, 2023 11:45 ET
|
Mithra Pharmaceuticals
Mithra to hold five presentations on key role of estrogens in women’s health, including Estetrol (E4), at the ESG Congress in Amsterdam Five abstracts on the positive effect of E4 accepted for oral...
Mithra’s NEXTSTELLIS® granted additional patent in the United States
November 07, 2023 01:00 ET
|
Mithra Pharmaceuticals
Mithra’s NEXTSTELLIS® granted additional patent in the United States New patent extends protection for NEXTSTELLIS® (ESTELLE®) until...
Mithra releases invitation to its extraordinary securities holders’ meeting
November 06, 2023 12:52 ET
|
Mithra Pharmaceuticals
Mithra releases invitation to its extraordinary securities holders’ meeting Liege, Belgium, 06 November 2023 – 17:45 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to...
Mithra and Searchlight Pharma sign DONESTA® licensing agreement for Canada
October 26, 2023 01:00 ET
|
Mithra Pharmaceuticals
Mithra and Searchlight Pharma sign DONESTA® licensing agreement for Canada Mithra to receive EUR 1.5 million milestone payout as a result of the signing...
Mithra to receive EUR 2.5 million milestone payment from Fuji Pharma under ESTELLE® licensing agreement
October 23, 2023 01:00 ET
|
Mithra Pharmaceuticals
Mithra to receive EUR 2.5 million milestone payment from Fuji Pharma under ESTELLE® licensing agreement Relates to the submission of a marketing approval application in JapanMarks strong...